secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001493152-23-027730
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Biosciences Q2 net loss $2.2M; cash $3.8M; IRB approves key PF614 study
-------------------------------------------------------------------------------

- Net loss for Q2 2023 was $2.2 million versus $7.9 million in Q2 2022; EPS ($0.98) vs ($56.49).
- Cash and cash equivalents $3.8 million at June 30, 2023, up from $1.4 million at March 31; increase driven by May 2023 public offering with $7.0 million gross proceeds.
- R&D expenses decreased to $1.6 million in Q2 2023 from $5.3 million in Q2 2022 due to timing of clinical studies.
- IRB approval received for PF614-201 protocol, a key Phase 3 study; End of Phase 2 meeting with FDA anticipated later this year.
- Positive results from oral abuse potential study (PF614-104) and overdose protection Phase 1 study (PF614-MPAR-101) completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315223027730/0001493152-23-027730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315223027730/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer